PDF
(Download)
|
- Cocoa (Theobroma cacao)
- Peripheral Artery Disease
- Walking Autonomy
|
Date:
08-29-2014 | HC# 081431-503
|
Re: Dark Chocolate Intake Improves Walking Distance and Walking Time in Patients with Peripheral Artery Disease
Loffredo
L, Perri L, Catasca E, et al. Dark chocolate acutely improves walking autonomy
in patients with peripheral artery disease. J
Am Heart Assoc. July 2014;3(4). pii:
e001072. doi: 10.1161/JAHA.114.001072.
More
than a fifth of adults older than 70 years are affected by peripheral arterial
disease (PAD) in Western countries.1 A major symptom of the disease
is intermittent claudication (IC), pain caused by impaired blood flow to the
limbs during physical exercise. Reduced
blood flow in patients with PAD is the result of endothelial dysfunction,
reduced glucose oxidation, accumulation of toxic metabolites, impaired nitric
oxide (NO) generation, and/or oxidative stress. In an earlier study,2
oxidative stress resulted in impaired walking distance autonomy (WDA), while
inhibiting oxidative stress led to improved maximal walking distance (MWD).
Polyphenol-rich cocoa (Theobroma cacao) has been associated with artery
dilatation by reducing oxidative stress and increasing NO generation.3,4
In particular, dark chocolate enhances artery dilatation by lowering the
activation of NOX2, a subunit of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, which has been shown to exert vasoconstrictor activity in both
animals and humans. These authors conducted an interventional, crossover,
single-blinded study to measure the acute effect of dark chocolate on WDA,
artery dilatation, and NOX2-mediated oxidative stress in patients affected by
moderate-to-severe PAD.
Specifically,
the trial investigated the acute effect of 40 g chocolate (dark vs. milk) on
MWD, maximal walking time (MWT), ankle brachial index (ABI) at rest and
postexercise, flow-mediated dilatation (FMD), oxidative stress, and NO
generation. Oxidative stress was assessed through blood levels of NOX-2
derivative peptide (sNOX2-dp; a marker of NOX2 activation) and isoprostanes.
Serum levels of nitrite-nitrate (NOx) were used to evaluate NO generation.
The
study, conducted between January 2012 and September 2013, included 20 patients
with PAD with IC. At baseline, all patients underwent a full medical history
and physical examination and answered a questionnaire about their fruit and
vegetable intake. They were randomly assigned to receive either 40 g dark
chocolate (≥85% cocoa) or milk chocolate (≤35% cocoa) in a crossover design,
with at least 1 week separating the 2 intervention phases. The modified
Folin-Ciocalteu colorimetric method used to determine the polyphenol content of
the chocolate revealed a significantly higher total and single polyphenol
content in the dark compared with the milk chocolate (P<0.001).
On
study visit days, fasting blood samples were collected, followed by the first
ABI and FMD at rest. The patients then completed the first treadmill test,
after which MWD and MWT were measured and postexercise ABI was performed. The patients
consumed 40 g of dark or milk chocolate. Two hours later, blood samples were
again collected to analyze oxidative stress markers and epicatechin levels, and
a second ABI and FMD evaluation was conducted. After 20 minutes, each patient completed
a second treadmill test to determine MWD and MWT, followed by another
postexercise ABI.
Compared
with baseline, no difference was observed 2 hours after milk chocolate
consumption in serum epicatechin, its metabolite EC-3-O-methylether, or
epigallocatechin-3-gallate (EGCG) levels; however, the levels of serum catechin
increased significantly. Two hours after dark chocolate intake, serum levels of
epicatechin and its metabolite EC-3-O-methylether, catechin, and EGCG increased
compared with baseline values.
Compared
with baseline, MWD and MWT increased after dark chocolate intake (P<0.001
for both) but not after milk chocolate intake. This is a novel finding, according
to the authors, noting that it supports the hypothesis that polyphenol content
may be responsible for this effect, as dark chocolate is richer in polyphenols
than milk chocolate.5
In
a within-group analysis, no significant effect on ABI at rest or after exercise
was observed after dark or milk chocolate intake. The analysis of variance
performed on the study data revealed a significant difference for treatments in
FMD (P=0.003); sNOX2-dp release (P=0.04); serum 8-iso-prostaglandin F2α-III, an
indicator of lipid peroxidation (P=0.018); MWD (P=0.01); MWT (P=0.006); and
postexercise ABI (P=0.04).
Pairwise
comparisons showed that sNOX2-dp (P<0.001) and serum isoprostanes (P=0.01)
significantly decreased after dark chocolate consumption but not after milk
chocolate intake. FMD (P<0.001) and NOx
(P=0.001) increased after dark chocolate intake, but no changes were
observed after milk chocolate intake.
Performing
a multiple linear regression analysis using a forward selection, the authors
report "that Δ of MWD was independently associated with Δ of MWT
(P<0.001) and Δ of NOx (P=0.018)."
The
authors conducted an accompanying in vitro study in which human umbilical vein
endothelial cells (HUVECs) were cultured to analyze the effect of scalar doses
of single polyphenols such as epicatechin, catechin, or EGCG or a mixture of
those on HUVEC activation. They found that HUVECs incubated with a mixture of
polyphenols significantly increased NO (P<0.001). Significant decreases were
seen in levels of E-selectin (P<0.001) and soluble vascular adhesion
molecule-1 (P<0.001) (both associated with cardiovascular disease risk).
The
vasodilating effect of dark chocolate could be due to the antioxidant effect of
its polyphenols, which has been documented in humans through reduction of
oxidative stress markers and an increase in its plasma antioxidant property. In
this study, the patients who consumed dark chocolate experienced short-term
changes in oxidative stress elicited by reduced serum isoprotanes, reduced NOX2
activity, and enhanced generation of NO. "These data may lead to
speculation that the enhanced NO generation could be responsible for artery
dilatation and eventually improve WDA," write the authors.
Referring
to the study's limitations, the authors suggest that although the study is
useful in understanding the mechanism of disease related to IC, the results are
not transferable to clinical practice because of the small sample size and
study design (single-blinded with no placebo group). Also, they say, only
indirect evidence suggests that vasodilation is the mechanism behind the
increase in walking autonomy; a direct analysis of peripheral circulation was
not done.
"The
results of this study suggest that short-term administration of dark chocolate
improves walking autonomy with a mechanism involving its high content of
polyphenols and perhaps mediated by an oxidative stress mechanism, which
ultimately leads to enhanced NO generation." A longer duration of dark
chocolate intake should be studied to assess whether it could be used to treat
IC in patients with PAD.
—Shari
Henson
References
1Hirsch AT, Haskal ZJ,
Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of
patients with peripheral arterial disease (lower extremity, renal, mesenteric,
and abdominal aortic): A collaborative report from the American Association for
Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography
and Interventions, Society for Vascular Medicine and Biology, Society of
Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing
Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial
Disease): Endorsed by the American Association of Cardiovascular and Pulmonary
Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular
Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease
Foundation. Circulation. 2006;113(11):e463-e654.
2Loffredo L, Pignatelli
P, Cangemi R, et al. Imbalance between nitric oxide generation and oxidative
stress in patients with peripheral arterial disease: effect of an antioxidant
treatment. J Vasc Surg.
2006;44(3):525-530.
3Loffredo L, Carnevale
R, Perri L, et al. NOX2-mediated arterial dysfunction in smokers: acute effect
of dark chocolate. Heart.
2011;97(21):1776-1781.
4Heiss C, Kleinbongard
P, Dejam A, et al. Acute consumption of flavanol-rich cocoa and the reversal of
endothelial dysfunction in smokers. J Am
Coll Cardiol. 2005;46(7):1276-1283.
5Langer S, Marshall
LJ, Day AJ, Morgan MR. Flavanols and methylxanthines in commercially available
dark chocolate: a study of the correlation with nonfat cocoa solids. J Agric Food Chem.
2011;59(15):8435-8441.
|